Tonix Pharmaceuticals Approved for Nasdaq Global Select Market Listing

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the open of market on March 3, 2026, under the existing ticker symbol “TNXP.” The move reflects the company’s compliance with the Nasdaq Global Select Market’s more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.

In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.

The Nasdaq Global Select Market listing represents a significant corporate achievement, as it requires companies to meet the highest initial listing standards of any Nasdaq market tier. This includes more rigorous financial, liquidity, and corporate governance requirements compared to the Nasdaq Capital Market. For Tonix, this transition signals to investors that the company has achieved a level of stability and compliance that aligns with larger, more established public companies. The enhanced market recognition could potentially attract a broader base of institutional investors who may have previously been restricted from investing in stocks listed on lower-tier exchanges.

This development comes as Tonix continues to expand its commercial and clinical footprint. The company’s focus on CNS disorders and immunology addresses significant market needs, with conditions like fibromyalgia, migraine, and rare diseases affecting millions globally. The uplisting may provide Tonix with improved access to capital markets, which could be crucial for funding ongoing clinical trials and potential commercialization efforts for its pipeline candidates. While the immediate trading impact will be observed in 2026, the approval itself serves as a validation of Tonix’s corporate trajectory and operational maturity within the competitive biotechnology sector.